Literature DB >> 15258184

Differential expression of CD44 during human prostate epithelial cell differentiation.

Tahirah N Alam1, Michael J O'Hare, István Laczkó, Alex Freeman, Farah Al-Beidh, John R Masters, David L Hudson.   

Abstract

CD44 is a polymorphic transmembrane glycoprotein that binds hyaluronan and growth factors. Multiple isoforms of the protein can be generated by alternative splicing but little is known about the expression and function of these isoforms in normal development and differentiation. We have investigated the expression of CD44 during normal prostate epithelial cell differentiation. A conditionally immortalized prostate epithelial cell line, Pre2.8, was used as a model system. These cells proliferate at 33C but at 39C stop dividing and undergo changes consistent with early stages of cell differentiation. During the differentiation of these cells, the expression of the CD44 isoform v3-v10 was upregulated. Two layers of epithelial cells can clearly be distinguished in the human prostate, a basal layer expressing keratins 5/14 and a luminal layer expressing keratins 8/18. In prostate tissue the v3-v10 isoform was found predominantly in basal cells but also in keratin 14-negative, keratin 19-positive cells intermediate between the two layers. CD44 v3-v10 was also expressed in other keratin 14-negative prostate tissues, the ejaculatory ducts and prostatic urethra. Therefore, CD44 v3-v10 may be important as a cell surface marker for differentiating cells in the prostate epithelium.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15258184     DOI: 10.1369/jhc.4A6256.2004

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  9 in total

1.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Authors:  Shihua Sun; Cynthia C T Sprenger; Robert L Vessella; Kathleen Haugk; Kathryn Soriano; Elahe A Mostaghel; Stephanie T Page; Ilsa M Coleman; Holly M Nguyen; Huiying Sun; Peter S Nelson; Stephen R Plymate
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

Review 2.  Prostate epithelial stem cells.

Authors:  S Rizzo; G Attard; D L Hudson
Journal:  Cell Prolif       Date:  2005-12       Impact factor: 6.831

Review 3.  Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Anticancer Agents Med Chem       Date:  2010-02       Impact factor: 2.505

Review 4.  CD44 as a potential diagnostic tumor marker.

Authors:  Nawwaf S Basakran
Journal:  Saudi Med J       Date:  2015-03       Impact factor: 1.484

Review 5.  The role of CD133 in cancer: a concise review.

Authors:  Paige M Glumac; Aaron M LeBeau
Journal:  Clin Transl Med       Date:  2018-07-09

6.  TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.

Authors:  J F Knight; C J Shepherd; S Rizzo; D Brewer; S Jhavar; A R Dodson; C S Cooper; R Eeles; A Falconer; G Kovacs; M D Garrett; A R Norman; J Shipley; D L Hudson
Journal:  Br J Cancer       Date:  2008-11-11       Impact factor: 7.640

7.  Prostate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2.24.

Authors:  Galina I Botchkina; Edison S Zuniga; Rebecca H Rowehl; Rosa Park; Rahuldev Bhalla; Agnieszka B Bialkowska; Francis Johnson; Lorne M Golub; Yu Zhang; Iwao Ojima; Kenneth R Shroyer
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

Review 8.  Prostate Cancer Stem Cells: Research Advances.

Authors:  Dagmara Jaworska; Wojciech Król; Ewelina Szliszka
Journal:  Int J Mol Sci       Date:  2015-11-17       Impact factor: 5.923

9.  Association of Single-Nucleotide Polymorphisms of CD44 Gene with Susceptibility to Breast Cancer in Chinese Women.

Authors:  Xiao Lin; Xiaojing You; Xuezhen Cao; Shenghua Pan
Journal:  Med Sci Monit       Date:  2018-05-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.